PSA and Prostate Screening: The Nuanced Decision

TL;DR: The PSA blood test can find prostate cancer early, and for some men that is lifesaving. It also finds many slow-growing cancers that would never have caused a problem, and the biopsies and treatment that can follow carry meaningful side effects, which is why prostate screening is one of the more nuanced decisions in men's health. The modern answer is not to screen everyone or no one, but to make an individual decision based on age and risk, and to use smarter follow-up (a prostate MRI before any biopsy, and active surveillance for low-risk cancers) to capture the benefit while avoiding much of the harm. Guidelines favor shared decision-making for men 50 to 69, and earlier for Black men and those with a family history. At Fishtown Medicine we walk through this decision with you rather than defaulting to a reflex either way.

If you are a man weighing whether to get a PSA test, or you have one back and are not sure what it means, this page lays out the trade-offs that matter. Prostate screening has swung from routine to discouraged and back toward a thoughtful middle, and the reason is worth understanding, because the right answer depends on you.

What is the PSA test and what does it measure?

PSA (prostate-specific antigen) is a protein made by the prostate, and the PSA test measures its level in the blood. A higher level can be a sign of prostate cancer, which is why it is used for screening. The complication is that PSA is not specific to cancer: it also rises with benign prostate enlargement (BPH), prostatitis (inflammation or infection), recent ejaculation, and simply with age. So a raised PSA raises a question rather than delivering an answer.

This is the root of the whole debate. A high PSA often leads to more testing, and historically that meant proceeding straight to a prostate biopsy, which carries discomfort and a risk of infection and bleeding. Many of those biopsies found either nothing or a slow-growing cancer that would never have caused harm. Understanding that the test flags possibilities, not diagnoses, is the key to using it well.

Should you get a PSA test? The overdiagnosis problem

Whether you should get a PSA test comes down to balancing a meaningful benefit against a meaningful harm, which is why guidelines call for a shared decision rather than a blanket rule. The benefit is that screening can catch aggressive prostate cancer early, and large trials have shown it modestly reduces prostate cancer deaths.² The harm is overdiagnosis: because many prostate cancers grow so slowly that they would never threaten a man's life, screening can lead to diagnosis and treatment of cancers that were better left alone, and prostate cancer treatment can cause urinary and sexual side effects.

The US Preventive Services Task Force reflects this balance by recommending that men aged 50 to 69 make an individual decision about PSA screening after discussing the trade-offs, rather than screening automatically or not at all.¹ It recommends against routine screening after age 70. The point is that there is no single right answer for every man; the decision depends on your age, your risk, your health, and how you weigh the possibility of catching a dangerous cancer against the possibility of being treated for one that never needed it.

Who is at higher risk and should consider screening earlier?

Some men carry enough extra risk that the balance tips toward starting screening earlier, often at 45 or even 40. The main higher-risk groups are:

• Black men, who have a higher incidence of prostate cancer and a higher rate of aggressive disease, and who are often advised to start the conversation at 45.
• Men with a family history, particularly a father or brother diagnosed with prostate cancer, and more so if it was diagnosed young or was aggressive.
• Men with certain inherited genetic mutations, such as BRCA2, which raise the risk of aggressive prostate cancer.

For these men, the earlier and more attentive approach reflects a meaningfully higher chance of the kind of cancer that screening is meant to catch. This is also why family history and ancestry are part of the screening conversation rather than an afterthought.

How do modern workups reduce the harm of screening?

The biggest change in prostate screening is not the PSA test itself but what happens after a high result, and it has made the whole process safer and smarter. Two advances do most of the work:

• Prostate MRI before biopsy. Instead of jumping to a biopsy after a high PSA, an MRI of the prostate can show whether there is a suspicious area worth sampling. This spares many men a biopsy altogether and makes the biopsies that do happen more accurate.³
• Active surveillance for low-risk cancer. When a low-risk, slow-growing prostate cancer is found, it can often be monitored with regular testing rather than treated immediately, avoiding the side effects of surgery or radiation unless the cancer shows signs of progressing. In long-term follow-up, this proved safe for appropriately selected men.⁴

Together these changes address the core criticism of old-style screening. They let the PSA test do its job of flagging risk while cutting down on unnecessary biopsies and the overtreatment of cancers that never needed it, which moves the benefit-to-harm balance in the patient's favor.

How Fishtown Medicine approaches prostate screening in Philadelphia

We treat the PSA decision as what it is, a decision, made with you rather than for you. That starts with your age, your ancestry, your family history, and your own values, and an honest conversation about what a PSA test can and cannot tell you. For men who choose to screen, we track PSA over time, because the trend and the velocity often matter more than a single number, and we interpret a raised result in context rather than reacting to it.

When a PSA warrants a closer look, we favor the modern path, a prostate MRI before any biopsy, and we refer to highly qualified urology specialists who are in network for you for the MRI, biopsy, and any treatment decisions, coordinating the results into your plan. For low-risk cancers, we support the active-surveillance approach where it fits, and for complex cases we compare notes across a network of specialists. Whether you are in Fishtown or Rittenhouse, or across the bridge in Cherry Hill or Moorestown, the aim is to capture the benefit of screening while sparing you the harms it can cause.

Guidance from the Clinic

"Prostate screening is one of the few places in medicine where the honest answer is 'it depends,' and I would rather have the full conversation than give a reflex yes or no. My job is to lay out that a PSA can catch a dangerous cancer early, and that it can also send someone down a road of biopsies and treatment for a cancer that never would have bothered them. The good news is that we have gotten much smarter about the follow-up, an MRI before any biopsy, watchful monitoring for the slow cancers. That lets us keep the upside and cut most of the downside, and it is why I am comfortable screening the right man at the right time."

Related at Fishtown Medicine

• Advanced Cancer Screening - the broader early-detection picture
• Colorectal Cancer Screening - another prevention decision worth getting right
• The Four Horsemen: The Diseases That End Most Lives - where cancer fits the longevity picture
• Testosterone Replacement Therapy in Philadelphia - men's health and the prostate question
• Executive Physical in Philadelphia - how screening fits a full workup

Scientific References

1. US Preventive Services Task Force. "Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement." JAMA. 2018;319(18):1901-1913.
2. Schröder FH, Hugosson J, Roobol MJ, et al. "Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up." Lancet. 2014;384(9959):2027-2035.
3. Kasivisvanathan V, Rannikko AS, Borghi M, et al. "MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis." New England Journal of Medicine. 2018;378(19):1767-1777.
4. Hamdy FC, Donovan JL, Lane JA, et al. "10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer." New England Journal of Medicine. 2016;375(15):1415-1424.